Cepheid News
Neutral Rating Restated for Cepheid - Analyst Blog
Zacks May 13We maintain our Neutral recommendation on Cepheid following first-quarter 2013 results.
CEPHEID Financials
May 10Cepheid Welcomes Executive Vice President of Global Operations
PR Newswire May 7SUNNYVALE, Calif., May 7, 2013 /PRNewswire/ -- Cepheid (NASDAQ: CPHD) today announced that it has appointed Warren C. Kocmond to the position of Executive Vice President, Global Operations, effective May ...
DexCom Loss Narrower than Est. - Analyst Blog
Zacks May 2Dexcom's loss shrinks year over year in the first quarter 2013 on higher revenues.
Cepheid to Webcast Upcoming Financial Presentations
PR Newswire May 1SUNNYVALE, Calif., May 1, 2013 /PRNewswire/ -- Cepheid (NASDAQ: CPHD) today announced that its executives will be speaking at the following conferences, and invited investors to participate via webcast. ...
Huge Earnings Miss By AMED, Guides Low - Analyst Blog
Zacks May 1Amedisys misses Zacks Consensus Estimate in the first quarter of 2013.
ResMed's Earnings Beat; Revs Lag - Analyst Blog
Zacks Apr 29ResMed reports a mixed third-quarter fiscal 2013.
FDA Taking More Aggressive Approach in Areas of Totally Unmet Medical Need, Granting Breakthrough Status to New Drugs in Development if No Other Therapeutic Option
Wall Street Transcript Apr 2667 WALL STREET, New York - April 26, 2013 - The Wall Street Transcript has just published its Biotechnology and Pharmaceuticals Report offering a timely review of the sector to serious investors and industry ...
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| CPHD | 38.27 | -0.25 | -0.65% | 2.568B |
